FIELD: biotechnology.
SUBSTANCE: described is a group of inventions including a phenylpyridine derivative represented by the chemical formula 1 or a pharmaceutically acceptable salt and pharmaceutical composition thereof for prevention or treatment of autoimmune or cancerous diseases mediated by interleukin-2-inducible tyrosine kinase (ITK) or Bruton's tyrosine kinase (BTK).
EFFECT: invention expands the range of means of prevention or treatment of autoimmune or cancerous diseases mediated by interleukin-2-inducible tyrosine kinase (ITK) or Bruton's tyrosine kinase (BTK).
12 cl, 1 tbl, 73 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW HETEROCYCLIC AMINE DERIVATIVE AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | 2019 |
|
RU2760184C1 |
| PYRROLOTRIAZINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2726632C1 |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | 2006 |
|
RU2411237C2 |
| HETEROARYL COMPOUNDS AS IRAK TYPE II INHIBITORS AND THEIR USE | 2019 |
|
RU2810338C2 |
| GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENT | 2008 |
|
RU2450001C2 |
| TETRAHYDROPYRIDINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | 2017 |
|
RU2722594C1 |
| COMPOUNDS AND COMPOSITIONS FOR MODULATING KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2822389C2 |
| BICYCLIC AMINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | 2007 |
|
RU2465275C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
